NASDAQ:GRTX Galera Therapeutics - GRTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.13 -0.06 (-2.74%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.11▼$2.3050-Day Range$1.59▼$2.4752-Week Range$1.12▼$2.75Volume544,764 shsAverage Volume860,073 shsMarket Capitalization$91.23 millionP/E RatioN/ADividend YieldN/APrice Target$8.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Galera Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside310.8% Upside$8.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 5 Articles This WeekInsider TradingAcquiring Shares$212,350 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.56) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector656th out of 983 stocksPharmaceutical Preparations Industry314th out of 478 stocks 3.5 Analyst's Opinion Consensus RatingGalera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.75, Galera Therapeutics has a forecasted upside of 310.8% from its current price of $2.13.Amount of Analyst CoverageGalera Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GRTX. Previous Next 0.0 Dividend Strength Dividend YieldGalera Therapeutics does not currently pay a dividend.Dividend GrowthGalera Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRTX. Previous Next 3.1 News and Social Media Coverage News SentimentGalera Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Galera Therapeutics this week, compared to 0 articles on an average week.Search Interest12 people have searched for GRTX on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Galera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galera Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $212,350.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.60% of the stock of Galera Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 36.45% of the stock of Galera Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Galera Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galera Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galera Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Galera Therapeutics (NASDAQ:GRTX) StockGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Read More Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTX Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comInsider Buying: Galera Therapeutics, Inc. (NASDAQ:GRTX) Insider Acquires 11,000 Shares of StockMarch 16, 2023 | americanbankingnews.comMel Sorensen Purchases 100,000 Shares of Galera Therapeutics, Inc. (NASDAQ:GRTX) StockMarch 22, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 15, 2023 | americanbankingnews.comGalera Therapeutics, Inc. (NASDAQ:GRTX) CFO Chris Degnan Buys 10,000 SharesMarch 10, 2023 | finance.yahoo.comGalera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck OncologyMarch 8, 2023 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say AnalystsMarch 8, 2023 | finanznachrichten.deGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate UpdatesMarch 8, 2023 | finance.yahoo.comGalera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate UpdatesMarch 22, 2023 | Investing Daily (Ad)Check Out This 6-Year Win StreakDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 2, 2023 | benzinga.comGalera Therapeutics Chief Financial Officer Awarded $331K Worth of Stock OptionsMarch 1, 2023 | benzinga.comGalera Therapeutics Chief Operating Officer Awarded $241K Worth of Stock OptionsMarch 1, 2023 | benzinga.comPresident and CEO at Galera Therapeutics Acquires Company Stock Options Worth 440,000 SharesMarch 1, 2023 | benzinga.comGalera Therapeutics Chief Commercial Officer Awarded $241K Worth of Stock OptionsFebruary 23, 2023 | 247wallst.comPiper Sandler Initiates Coverage of Galera Therapeutics With Overweight RecommendationFebruary 15, 2023 | finance.yahoo.comGalera Therapeutics expects to raise $30M from direct stock offeringFebruary 15, 2023 | marketwatch.comGalera Therapeutics Shares Rise Premarket on FDA Priority Review >GRTXFebruary 15, 2023 | finance.yahoo.comGalera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral MucositisFebruary 15, 2023 | finance.yahoo.comGalera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and WarrantsDecember 12, 2022 | finance.yahoo.comMalvern-based Galera shares rise on FDA filing for lead cancer therapy drugDecember 12, 2022 | finance.yahoo.comGalera Submits New Drug Application for Avasopasem for Severe Oral MucositisNovember 22, 2022 | finance.yahoo.comGalera to Present at Piper Sandler Annual Healthcare ConferenceNovember 9, 2022 | finanznachrichten.deGalera Therapeutics: Galera Reports Third Quarter 2022 Financial Results and Recent Corporate UpdatesNovember 9, 2022 | finance.yahoo.comGalera Reports Third Quarter 2022 Financial Results and Recent Corporate UpdatesNovember 7, 2022 | finance.yahoo.comOne Galera Therapeutics, Inc. (NASDAQ:GRTX) insider upped their stake by 50% in the previous yearNovember 1, 2022 | finance.yahoo.comGalera Therapeutics' Avasopasem Reduces Chemo-Related Kidney Disease By 50% Versus Placebo At One-YearOctober 26, 2022 | finance.yahoo.comGalera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual MeetingSeptember 26, 2022 | finance.yahoo.comGalera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual MeetingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GRTX Company Calendar Last Earnings11/10/2021Today3/21/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRTX CUSIPN/A CIK1563577 Webwww.galeratx.com Phone610-725-1500FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.75 High Stock Price Forecast$12.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+310.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,220,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-109.68% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.83) per share Price / Book-0.56Miscellaneous Outstanding Shares42,830,000Free Float39,147,000Market Cap$91.23 million OptionableNot Optionable Beta1.75 Key ExecutivesDr. J. Mel Sorensen M.D. (Age 65)CEO, Pres & Director Comp: $820.77kMr. Christopher Degnan (Age 42)Chief Financial Officer Comp: $529.35kMr. Mark J. Bachleda M.B.A. (Age 47)Pharm.D., Chief Commercial Officer Comp: $476.5kDr. Robert A. Beardsley M.B.A. (Age 60)Ph.D., Co-Founder & COO Dr. Dennis P. Riley Ph.D.Chief Scientific Officer, EmeritusMs. Jennifer Evans Stacey Esq. (Age 57)Chief Legal & Compliance Officer and Sec. Dr. Jon T. Holmlund M.D. (Age 65)Exec. Officer Ms. Andie CollierSr. VP of Regulatory AffairsMs. Judy SchnyderSr. VP of Clinical Operations & Data ManagementDr. Eugene P. Kennedy F.A.C.S. (Age 53)FACS, M.D., Chief Medical Officer More ExecutivesKey CompetitorsNuCanaNASDAQ:NCNAAnebulo PharmaceuticalsNASDAQ:ANEBSyros PharmaceuticalsNASDAQ:SYRSAssembly BiosciencesNASDAQ:ASMBBellerophon TherapeuticsNASDAQ:BLPHView All CompetitorsInsiders & InstitutionsMark BachledaBought 11,000 shares on 3/16/2023Total: $24,750.00 ($2.25/share)Chris DegnanBought 10,000 shares on 3/13/2023Total: $19,600.00 ($1.96/share)Mel SorensenBought 100,000 shares on 3/10/2023Total: $168,000.00 ($1.68/share)Geode Capital Management LLCBought 9,273 shares on 2/13/2023Ownership: 0.614%Renaissance Technologies LLCSold 115,268 shares on 2/13/2023Ownership: 0.149%View All Insider TransactionsView All Institutional Transactions GRTX Stock - Frequently Asked Questions Should I buy or sell Galera Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GRTX shares. View GRTX analyst ratings or view top-rated stocks. What is Galera Therapeutics' stock price forecast for 2023? 3 Wall Street analysts have issued twelve-month target prices for Galera Therapeutics' shares. Their GRTX share price forecasts range from $6.00 to $12.00. On average, they predict the company's stock price to reach $8.75 in the next year. This suggests a possible upside of 310.8% from the stock's current price. View analysts price targets for GRTX or view top-rated stocks among Wall Street analysts. How have GRTX shares performed in 2023? Galera Therapeutics' stock was trading at $1.49 at the beginning of the year. Since then, GRTX shares have increased by 43.0% and is now trading at $2.13. View the best growth stocks for 2023 here. When is Galera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our GRTX earnings forecast. How were Galera Therapeutics' earnings last quarter? Galera Therapeutics, Inc. (NASDAQ:GRTX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15. What other stocks do shareholders of Galera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV). When did Galera Therapeutics IPO? (GRTX) raised $75 million in an IPO on Thursday, November 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager. What is Galera Therapeutics' stock symbol? Galera Therapeutics trades on the NASDAQ under the ticker symbol "GRTX." Who are Galera Therapeutics' major shareholders? Galera Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sectoral Asset Management Inc. (5.85%), Geode Capital Management LLC (0.61%), Renaissance Technologies LLC (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bioventures Ltd Novartis, Chris Degnan, Holdings A/S Novo, Joel F Sussman, Jon T Holmlund, Linda West, Mark Bachleda and Mel Sorensen. View institutional ownership trends. How do I buy shares of Galera Therapeutics? Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galera Therapeutics' stock price today? One share of GRTX stock can currently be purchased for approximately $2.13. How much money does Galera Therapeutics make? Galera Therapeutics (NASDAQ:GRTX) has a market capitalization of $91.23 million. The company earns $-62,220,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. How can I contact Galera Therapeutics? Galera Therapeutics' mailing address is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. The official website for the company is www.galeratx.com. The company can be reached via phone at 610-725-1500 or via email at cdegnan@galeratx.com. This page (NASDAQ:GRTX) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.